Pulse Biosciences, Inc. (PLSE) |
| 53.81 3.83 (7.66%) 10-09 16:00 |
| Open: | 50.23 |
| High: | 53.94 |
| Low: | 50.23 |
| Volume: | 365,803 |
| Market Cap: | 3,724(M) |
| PE Ratio: | -45.6 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Instruments & Supplies |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 68.80 |
| Resistance 1: | 58.90 |
| Pivot price: | 51.03 |
| Support 1: | 51.74 |
| Support 2: | 47.31 |
| 52w High: | 58.9 |
| 52w Low: | 12.56 |
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
| EPS | -82620000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -5.00 |
| Return on Assets (ttm) | 823.0 |
| Return on Equity (ttm) | -44.3 |
Fri, 09 Oct 2026
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Thu, 08 Oct 2026
Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026 - Business Wire
Wed, 07 Oct 2026
Pulse Biosciences stock reaches 164 patient study target - AD HOC NEWS
Wed, 07 Oct 2026
Pulse Biosciences hits 164-patient enrollment target in NANOPULSE-AF pivotal IDE study - TradingView
Wed, 07 Oct 2026
A heart-rhythm trial reached its goal three months early, enrolling 164 evaluable patients. - Stock Titan
Wed, 07 Oct 2026
Canaccord raises target for Pulse Biosciences stock from USD 43.00 to USD 58.00 - AD HOC NEWS
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |